This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bennett, K. L. Articles by Plass, C. Search for Related Content PubMed Articles by Bennett, K. L. Articles by Plass, C.

Tumor Suppressor Activity of CCAAT/Enhancer Binding Protein Is Epigenetically Down-regulated in Head and Neck Squamous Cell Carcinoma

Departments of ¹ Molecular Genetics, ² Molecular Virology, Immunology, and Medical Genetics, Division of Human Cancer Genetics, and ³ Pathology and The Comprehensive Cancer Center, Ohio State University, Columbus, Ohio; ⁴ University of Freiburg Medical Center, Freiburg, Germany; and ⁵ Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic Foundation and Taussig Cancer Center, Cleveland, Ohio

Requests for reprints: Christoph Plass, Ohio State University, Division of Human Cancer Genetics, Tzagournis Medical Research Facility 464A, 420 W. 12th Avenue, Columbus, OH 43210. Phone: 614-292-6505; Fax: 614-688-4761; E-mail: Christoph.Plass{at}osumc.edu.

Tumor suppressor CCAAT enhancer binding protein (C/EBP) is a transcription factor involved in cell cycle control and cellular differentiation. In a recent study, microarray expression profiling on head and neck squamous cell carcinoma (HNSCC) samples identified significant C/EBP down-regulation, correlating with poor prognosis. However, the mechanisms of C/EBP down-regulation remained elusive. C/EBP has been previously found to provide an antiproliferative role in lung cancer, and our laboratory showed that its down-regulation involves epigenetic mechanisms. This prompted us to investigate the involvement of epigenetics in down-regulating C/EBP in HNSCC. Here, we show that C/EBP is down-regulated in HNSCC by loss of heterozygosity and DNA methylation, but not by gene mutation. We found a consistently methylated upstream regulatory region (–1,399 bp to –1,253 bp in relation to the transcription start site) in 68% of the HNSCC tumor samples, and DNA demethylation using 5-aza-2'-deoxycytidine treatment was able to significantly restore C/EBP mRNA expression in the HNSCC cell lines we tested. In addition, C/EBP overexpression in a HNSCC cell line (SCC22B) revealed its ability to provide tumor suppressor activity in HNSCC in vitro and in vivo. In conclusion, we showed for the first time not only that C/EBP has tumor suppressor activity in HNSCC, but also that it is down-regulated by DNA promoter methylation. [Cancer Res 2007;67(10):4657–64]

This article has been cited by other articles:

				M. E. Figueroa, B. J. Wouters, L. Skrabanek, J. Glass, Y. Li, C. A. J. Erpelinck-Verschueren, A. W. Langerak, B. Lowenberg, M. Fazzari, J. M. Greally, et al. Genome-wide epigenetic analysis delineates a biologically distinct immature acute leukemia with myeloid/T-lymphoid features Blood, March 19, 2009; 113(12): 2795 - 2804. [Abstract] [Full Text] [PDF]

				S. Koschmieder, B. Halmos, E. Levantini, and D. G. Tenen Dysregulation of the C/EBP{alpha} Differentiation Pathway in Human Cancer J. Clin. Oncol., February 1, 2009; 27(4): 619 - 628. [Abstract] [Full Text] [PDF]

				B. Hackanson, K. L. Bennett, R. M. Brena, J. Jiang, R. Claus, S.-S. Chen, N. Blagitko-Dorfs, K. Maharry, S. P. Whitman, T. D. Schmittgen, et al. Epigenetic Modification of CCAAT/Enhancer Binding Protein {alpha} Expression in Acute Myeloid Leukemia Cancer Res., May 1, 2008; 68(9): 3142 - 3151. [Abstract] [Full Text] [PDF]

				M. S. Hasemann, I. Damgaard, M. B. Schuster, K. Theilgaard-Monch, A. B. Sorensen, A. Mrsic, T. Krugers, B. Ylstra, F. S. Pedersen, C. Nerlov, et al. Mutation of C/EBP{alpha} predisposes to the development of myeloid leukemia in a retroviral insertional mutagenesis screen Blood, April 15, 2008; 111(8): 4309 - 4321. [Abstract] [Full Text] [PDF]